Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Cancer

Retrieve available abstracts of 46 articles:
HTML format

Single Articles

    May 2023
  1. BAEK GT, Huang IJ, Gopal AK
    Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Cancer. 2023 May 19. doi: 10.1002/cncr.34816.
    PubMed     Abstract available

  2. OERLEMANS S, Efficace F, Kyriakou C, Freitas AC, et al
    International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
    Cancer. 2023 May 19. doi: 10.1002/cncr.34822.
    PubMed     Abstract available

    Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:1466.

    FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.
    Cancer. 2023;129:1465-1466.

    March 2023
  5. AFIFY ZAM, Taj MM, Orjuela-Grimm M, Srivatsa K, et al
    Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Cancer. 2023;129:780-789.
    PubMed     Abstract available

    February 2023
  6. CHAKRABARTI D, Brahma Bhatt ML
    Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34712.

  7. ALEMAN BMP, Krul IM, Janus CPM, van der Maazen RWM, et al
    Reply to "Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?".
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34713.

  8. QUEUDEVILLE M, Stein AS, Locatelli F, Ebinger M, et al
    Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34667.
    PubMed     Abstract available

  9. CHO J, Kim E, Yoon SE, Kim SJ, et al
    TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34698.
    PubMed     Abstract available

  10. ALLEN PB, McCook-Veal AA, Switchenko JM, Paulino DM, et al
    Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
    Cancer. 2023;129:541-550.
    PubMed     Abstract available

  11. BODDU PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, et al
    A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Cancer. 2023;129:580-589.
    PubMed     Abstract available

  12. PENG Y, Zhao Q, Liao Z, Ma Y, et al
    Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Cancer. 2023 Feb 7. doi: 10.1002/cncr.34664.
    PubMed     Abstract available

    January 2023
  13. WONG CI, Vannatta K, Gilleland Marchak J, Quade EV, et al
    Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment.
    Cancer. 2023 Jan 27. doi: 10.1002/cncr.34651.
    PubMed     Abstract available

  14. GUIDETTI A, Dodero A, Lorenzoni A, Pizzamiglio S, et al
    Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
    Cancer. 2023;129:255-263.
    PubMed     Abstract available

    December 2022
  15. GAO Y, Liu Y, Wang Y, Zhang Q, et al
    Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
    Cancer. 2022 Dec 21. doi: 10.1002/cncr.34544.
    PubMed     Abstract available

    November 2022
  16. DUDLEY IM, Sunguc C, Heymer EJ, Winter DL, et al
    Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.
    Cancer. 2022 Nov 29. doi: 10.1002/cncr.34561.
    PubMed     Abstract available

  17. YANG J, Yu L, Man J, Chen H, et al
    Immune scoring model based on immune cell infiltration to predict prognosis in diffuse large B-cell lymphoma.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34519.
    PubMed     Abstract available

    October 2022
  18. KRUL IM, Boekel NB, Kramer I, Janus CPM, et al
    Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
    Cancer. 2022 Oct 25. doi: 10.1002/cncr.34464.
    PubMed     Abstract available

  19. PATEL PA, DeGroote NP, Jackson K, Cash T, et al
    Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia.
    Cancer. 2022 Oct 13. doi: 10.1002/cncr.34476.
    PubMed     Abstract available

  20. PATEL DA, Kahl BS
    Top advances in lymphoma for 2021.
    Cancer. 2022 Oct 6. doi: 10.1002/cncr.34483.
    PubMed     Abstract available

  21. YANG Y, Wang JJ, Zhao RZ, Huang C, et al
    The value of routine bone marrow examination in patients with extranodal NK/T-cell lymphoma staged with PET/CT.
    Cancer. 2022 Oct 1. doi: 10.1002/cncr.34473.
    PubMed     Abstract available

    September 2022
  22. HOLLEBECQUE A, Salvagni S, Plummer R, Niccoli P, et al
    Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
    Cancer. 2022;128:3185-3195.
    PubMed     Abstract available

    August 2022
  23. MA S, Zhang B, Lu T, Li D, et al
    Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
    Cancer. 2022 Aug 6. doi: 10.1002/cncr.34405.
    PubMed     Abstract available

  24. TAO R, Chen Y, Kim S, Ocier K, et al
    Mental health disorders are more common in patients with Hodgkin lymphoma and may negatively impact overall survival.
    Cancer. 2022 Aug 2. doi: 10.1002/cncr.34359.
    PubMed     Abstract available

    July 2022
  25. LU Z, Teng Y, Ning X, Wang H, et al
    Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.
    Cancer. 2022 Jul 25. doi: 10.1002/cncr.34375.
    PubMed     Abstract available

    April 2022
  26. RAJAMAKI A, Hujo M, Sund R, Prusila REI, et al
    Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34221.
    PubMed     Abstract available

  27. GANGARAJU R, Davis ES, Bhatia S, Kenzik KM, et al
    Venous-thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma.
    Cancer. 2022 Apr 1. doi: 10.1002/cncr.34210.
    PubMed     Abstract available

  28. HUTCHESON KA, Barbon CEA, Alvarez CP, Warneke CL, et al
    Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria: Validation of DIGEST version 2.
    Cancer. 2022;128:1458-1466.
    PubMed     Abstract available

    February 2022
  29. CHOW EJ, Aplenc R, Vrooman LM, Doody DR, et al
    Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
    Cancer. 2022;128:788-796.
    PubMed     Abstract available

  30. TORKA P, Akhtar OS, Reddy NM, Baysal BE, et al
    Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study.
    Cancer. 2022 Feb 14. doi: 10.1002/cncr.34106.
    PubMed     Abstract available

    January 2022

  31. Erratum to "Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation".
    Cancer. 2022 Jan 27. doi: 10.1002/cncr.33973.

  32. NOONE AM, Pfeiffer RM, Schaubel DE, Dorgan JF, et al
    Life-years lost due to cancer among solid organ transplant recipients in the United States, 1987 to 2014.
    Cancer. 2022;128:150-159.
    PubMed     Abstract available

    December 2021
  33. BACHIASHVILI K, Francisco L, Chen Y, Bosworth A, et al
    Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma.
    Cancer. 2021 Dec 28. doi: 10.1002/cncr.34072.
    PubMed     Abstract available

  34. WONG SM, Ajjamada L, Weiss AC, Prakash I, et al
    Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
    Cancer. 2021 Dec 17. doi: 10.1002/cncr.34065.
    PubMed     Abstract available

  35. UNGER JM, Beauchemin M, Hershman DL
    Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.
    Cancer. 2021;127:4574-4584.
    PubMed     Abstract available

    November 2021
  36. WADHWA A, Adams KM, Dai C, Richman JS, et al
    Association between body composition and chemotherapy-related toxicity in children with lymphoma and rhabdomyosarcoma.
    Cancer. 2021 Nov 30. doi: 10.1002/cncr.34043.
    PubMed     Abstract available

  37. LEUPIN N, Zinzani PL, Morschhauser F, Dalle S, et al
    Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
    Cancer. 2021 Nov 2. doi: 10.1002/cncr.34005.
    PubMed     Abstract available

    October 2021
  38. NERICH V, Guyeux C, Henry-Amar M, Couturier R, et al
    Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.
    Cancer. 2021 Oct 4. doi: 10.1002/cncr.33938.
    PubMed     Abstract available

    September 2021
  39. KAHN JM, Maguire FB, Li Q, Abrahao R, et al
    Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population-based study.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33868.
    PubMed     Abstract available

    August 2021
  40. KLISOVIC RB, Leung WH, Brugger W, Dirnberger-Hertweck M, et al
    A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33796.
    PubMed     Abstract available

    July 2021
  41. HU B, Boselli D, Pye LM, Chen T, et al
    Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma.
    Cancer. 2021 Jul 21. doi: 10.1002/cncr.33779.
    PubMed     Abstract available

  42. JUWEID ME, Mueller M, Alhouri A, A-Risheq MZ, et al
    Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Cancer. 2021 Jul 19. doi: 10.1002/cncr.33772.
    PubMed     Abstract available

    June 2021
  43. EL-GALALY TC, Ovlisen AK, Cheah CY
    Routine imaging for disease surveillance in follicular lymphoma-To comfort the patients or their doctors?
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33659.

  44. GOLDMAN ML, Mao JJ, Strouse CS, Chen W, et al
    Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33660.
    PubMed     Abstract available

    November 2020
  45. TOPP MS, Gokbuget N, Zugmaier G, Stein AS, et al
    Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Cancer. 2020 Nov 3. doi: 10.1002/cncr.33298.
    PubMed     Abstract available

    June 2020
  46. KARSCHNIA P, Batchelor TT, Jordan JT, Shaw B, et al
    Primary dural lymphomas: Clinical presentation, management, and outcome.
    Cancer. 2020;126:2811-2820.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.